Common GLP-1 Agonists Here is a list of some of the most common GLP-1 medications approved by the FDA: For Type 2 Diabetes: Adlyxin (lixisenatide) Ozempic (semaglutide) Rybelsus (semaglutide, oral tablet) Trulicity (dulaglutide) Victoza (liraglutide) Combination medications like Soliqua Vial (lixisenatide and insulin glargine) For Obesity: Saxenda (liraglutide) Wegovy (semaglutide) Zepbound (tirzepatide) Numerous other states are considering adding these medications because of the potential benefits of reducing obesity and the health complications it may prompt
Mobini M , Radbakhsh S , Kubaski F , et al
Summary of key recent findings on the various side effects of GLP-1 RAs GLP-1 RA, glucagon-like peptide-1 receptor agonist

the expected effect size is small and the onset is slow - Avoid antidepressants in bipolar depression presenting with subtle increased psychomotor tempo, pressured speech and racing thoughts due to the increased risk of switch and potentially rapid cycling - Consider ETC as a viable option for the treatment of bipolar depression resistant to pharmacological treatment - Never treat with antidepressants without a mood stabiliser - If an antidepressant is added, use mainly SSRIs due to their low switch rate - If an antidepressant is used in maintenance treatment, the occurrence of manic/mixed symptoms should be monitored carefully The above recommendation is consistent with current Danish guidelines for the pharmacological treatment of bipolar disorder [42], which recommend lithium, quetiapine and lamotrigine as first-line agents for bipolar I disorder, current depressive episode, in at least 70% of patients, and for bipolar II disorder, current depressive episode, in at least 60%

We will provide detailed administration protocols for both systemic (injectable) and topical use, addressing the critical need for precise, goal-oriented dosage information